NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- On February 16th, 2006 Shanghai Yutong Pharma, Inc. had filed their Form 10SB12G with the Securities and Exchange Commission in Washington, D.C. Upon successful approval by the SEC, the company will be eligible to list on the NASDAQ Over the Counter Bulletin Board Exchange.
Lu Jiang’an, President of Yutong stated, “It is our goal to become a fully reporting listed company. A higher exchange will improve our liquidity and enable better exposure for the company.”
About Shanghai Yutong Pharmaceuticals, Inc.
Through its subsidiary, Shanghai Yutong Pharmaceuticals, LTD, the company specializes in the development and commercialization of Chinese herbal medicines and biological pharmaceuticals. The Company operates from a 90,000 square foot GMP-approved facility and markets over 13 different types of Traditional Chinese Medicines. Qilisheng Oral Solution, the Company’s flagship product, has been granted a U.S. patent for its core technique.
Legal Disclaimer
The statements contained in this press release contain certain forward- looking statements, including statements regarding the company’s expectations, intentions, strategies and beliefs regarding the future. All statements contained herein are based upon information available to the company’s management as of the date hereof, and actual results may vary based upon future events, both within and without the control of the company’s management.
For Further Information: Rick Oravec rick@vircomglobal.com 212-422-3601
Shanghai Yutong Pharma, Inc.
CONTACT: Rick Oravec, for Shanghai Yutong Pharma,Inc.rick@vircomglobal.com or +1-212-422-3601
